RDF
Help
Browse wiki
From Glioblastoma Treatments
Jump to navigation
Jump to search
This page or action requires JavaScript to work. Please enable JavaScript in your browser or use a browser where it is supported, so that functionality can be provided as requested. For further assistance, please have a look at the
noscript
help page.
Phase II trial showed a significant improvement in PFS, particularly for HLA-A2 positive patients with methylated MGMT, showing a median PFS of 24.1 months vs. 8.5 months in the control group.
Hide groups
Hide incoming properties
Information is currently being retrieved from the backend.
Navigation menu
Page actions
Special page
Refresh
Page actions
Special page
Tools
Personal tools
Create account
Log in
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Search
Tools
Special pages
Printable version
